Previous work identified CD14+HLA-DRlo/neg monocytes as a predictor of poor prognosis and powerful mediators of immune suppression in GBM [8], NHL [9], chronic lymphocytic leukemia [18] melanoma [19], and renal cell cancer [20]. Here, CD14 is linked to melanoma.